Vericel - VCEL Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VCEL shares.
View VCEL analyst ratings or view top-rated stocks.

3 analysts have issued 1 year price targets for Vericel's shares. Their VCEL share price forecasts range from $33.00 to $45.00. On average, they anticipate the company's stock price to reach $37.33 in the next year. This suggests a possible upside of 32.7% from the stock's current price.
View analysts price targets for VCEL or view top-rated stocks among Wall Street analysts.

Vericel's stock was trading at $39.30 on January 1st, 2022. Since then, VCEL shares have decreased by 28.4% and is now trading at $28.13.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our VCEL earnings forecast.

Vericel Co. (NASDAQ:VCEL) announced its earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.08. The biotechnology company earned $34.51 million during the quarter, compared to analyst estimates of $38.07 million. Vericel had a negative trailing twelve-month return on equity of 9.75% and a negative net margin of 10.60%. The company's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter last year, the business earned $0.08 EPS.

Vericel issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $178.00 million-$189.00 million, compared to the consensus revenue estimate of $182.20 million.

6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Vericel's stock is owned by many different institutional and retail investors. Top institutional investors include Conestoga Capital Advisors LLC (3.62%), Allspring Global Investments Holdings LLC (2.03%), Loomis Sayles & Co. L P (1.74%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (1.61%), JPMorgan Chase & Co. (1.41%) and Northern Trust Corp (1.11%). Insiders that own company stock include Dominick Colangelo, Gerard J Michel, Jonathan Mark Hopper, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman.
View institutional ownership trends.

Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VCEL stock can currently be purchased for approximately $28.13.

Vericel (NASDAQ:VCEL) has a market capitalization of $1.33 billion and generates $156.18 million in revenue each year. The biotechnology company earns $-7,470,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

The company employs 281 workers across the globe.

Vericel was founded in 1989.

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.vcel.com. The biotechnology company can be reached via phone at (800) 556-0311, via email at ir@vcel.com, or via fax at 617-588-5554.